The PROREPAIR-B study showed that patients with metastatic prostate cancer and germline BRCA2 mutations exhibited a shorter time to developing castration resistance compared with non-carriers, suggesting that tumors in BRCA2 mutation carriers may be less reliant on AR signaling pathways. This evidence concerns the gene AR and metastatic prostate carcinoma.